No deal for foreseeable future. Larry has all the money he needs and wants to see how far this company can go on its own. With Rytary approval, this stock can grow in leaps and bounds. Several other branded products on the slate through acquisitions. This drop after earnings is a gift for the LT investor of IPXL.
I agree on your sentiment but Teva has to be the Lion licking its chops as they need to close the immediate and forseable gap on Parkinsons competition. I have studied and learned that Rytary is the most effective Parkinson's medication coming to market.
Teva may just step in and swallow hole Impax as they are partners on many other fronts. Larry is wealthy, but greed is greed and a stock swap with Teva would be too hard to pass up.